< 回列表
吳子丑
- Professor and Director, Division of Gynecologic Pathology, The Johns Hopkins University
- Professor of Oncology, The Johns Hopkins University
- Professor of Obstetrics and Gynecology, The Johns Hop0kins University
- Professor of Molecular Microbiology and Immunology, The Johns Hopkins University Bloomberg
Development of Antigen-Specific Cancer Immunotherapy: From Bench to Bedside
| 角色 | 講師 |
| 日期時間 | 05/02 09:00 - 09:30 |
| 地點 | 701B |
學歷 / 訓練
1982, M.D., College of Medicine, National Taiwan University
1989, PhD., Molecular Virology, The Johns Hopkins University
專業與研究經歷
1989 - 1992, Resident, Anatomic Pathology, The Johns Hopkins University
1982 - 1995, Clinical Research Fellow, Division of Gynecologic Pathology, The Johns Hopkins University
獲獎與榮譽
2003
Elected member, American Society for Clinical Investigation (ASCI)
2012
Elected member , Association of American Physicians (AAP)
2016
Academician, Academia Sinica
2019
Elected member, American Academy of Microbiology
重要出版品
- Lam B, Kung YJ, Lin J, Tseng SH, Tu HF, Huang C, Lee B, Velarde E, Tsai YC, Villasmil R, Park ST, Xing D, Hung CF, Wu TC. In situ vaccination via tissue-targeted cDC1 expansion enhances the immunogenicity of chemoradiation and immunotherapy. J Clin Invest. 2024 Jan 2;134(1):e171621. doi: 10.1172/JCI171621. PMID: 37917174; PMCID: PMC10760964.
- Peng S, Xing D, Ferrall L, Tsai YC, Hung CF, Wu TC. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice. J Biomed Sci. 2022 Oct 12;29(1):80. doi: 10.1186/s12929-022-00864-5. PMID: 36224625; PMCID: PMC9554842.
- Henkle TR, Lam B, Kung YJ, Lin J, Tseng SH, Ferrall L, Xing D, Hung CF, Wu TC. Development of a novel mouse model of spontaneous high-risk HPVE6/E7-expressing carcinoma in the cervicovaginal tract. Cancer Res. 2021 Jul 2. PMID: 34215618.
- W.-F. Cheng, C.-F. Hung, C.-Y. Chai, K.-F. Hsu, L. He, M. Ling and T.-C. Wu. (2001) Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. 108(5): 669-78.
- K.-Y. Lin, F.G. Guarnieri, K.F. Staveley-O'Carroll, H.I. Levitsky, J.T. August, D.M. Pardoll and T.-C. Wu (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56(1): 21-26.